News

High Risk Suppliers

Published on
| 2 years ago
Programmes
  • MSCA
  • Health
  • Civil Security
  • Digital, Industry & Space
  • Climate, Energy, Mobility
  • Agro-Food, Environment
  • Missions
  • Horizon Europe

The European Union recently published a political commitment to strengthen the ICT supply-chain security and proposed a new plan to expand and reinforce its EU-wide cyber defence capabilities, reaffirming its commitment to the security of its digital infrastructure and to international law and norms in cyberspace.

This also impacts Horizon Europe, as in the General Annexes of the Work Programme 23-25 "Restrictions for the protection of European communication networks" has been added as an eligbility condition (p. 7).

Entities that are assessed as high-risk suppliers of mobile network communication equipment (and any entities they own or control) are not eligible to participate as beneficiaries, affiliated entities and associated partners.

This restriction applies to proposals within the Marie Skłodowska-Curie Actions part that concern the evolution of European communication networks (5G, post-5G and other technologies linked to the evolution of European communication networks) and 35 actions in pillar 2 (only in calls opening after the publication of this amended Work Programma, 18 April 2024), where the call topic contains the specific ‘eligibility’ condition “Subject to restrictions for the protection of European communication networks”. 

  • Cluster 1 –1 action
  • Cluster 3 –19 actions
  • Cluster 4 –1 action
  • Cluster 5 –8 actions
  • Cluster 6 –1 action
  • Missions –5 actions

This eligibility rule will be assessed at Grant Agreement Preparation phase by the project officer.

Related news

myOverview

Sign up for personalised information

Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.

  • News in your domains
  • Event announcements
  • A personal dashboard
Sign up now

Only for stakeholders located in Flanders

Latest news

2062 articles available Browse all news
  • EIT
  • New European Bauhaus

Catalyse NEB Open Call 2027 launched

The New European Bauhaus Community of EIT (European Institute of Innovation and Technology) has opened the Catalyse NEB Open Call 2027. The call concerns its accelerator programme for start-ups and is linked to the New European Bauhaus. The programme aims to support 20 for-profit start-ups incorporated after 1 January 2022 in an eligible country....

Read more
  • Climate, Energy, Mobility
  • EIT

2027 SME Market Expansion Call of EIT Urban Mobility

EIT Urban Mobility has opened the SME Market Expansion Open Call 2027. The call is designed for small and medium-sized enterprises that want to expand proven urban mobility solutions into new markets, regions or sectors. Applications must be supported by an end client, either a public or private entity, that is committed to testing and...

Read more
  • ERC

First edition of ERC Success Stories from Widening Countries

The network of National Contact Points (NCPs) for the European Research Council (ERC), mERCury, has recently published the first edition of the ERC Success Stories from Widening countries. The collection features seven ERC grantees from Malta, Croatia, Romania, Slovenia, Latvia, Greece and Türkiye who have received Starting, Consolidator,...

Read more

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.